[Survey of Tumor Necrosis Factor Inhibitors Application in Patients with Rheumatoid Arthritis in China].
Xiu-ru Wang,Yin Su,Yuan An,Yun-shan Zhou,Xiao-ying Zhang,Tian-jiao Duan,Jia-xin Zhu,Xiao-feng Li,Cai-hong Wang,Li-zhi Wang,Yong-fu Wang,Rong Yang,Guo-chun Wang,Xin Lu,Ping Zhu,Li-Na Chen,Yi Wang,Xiao-Yuan Wang,Hong-Tao Jin,Jin-Ting Liu,Hai-Ying Chen,Ping Wei,Jun-Xiang Wang,Xiang-Yuan Liu,Lin Sun,Liu-Fu Cui,Rong Shu,Bai-lu Liu,Zhuo-li Zhang,Guang-tao Li,Zhen-bin Li,Jing Yang,Jun-fang Li,Bin Jia,Feng-xiao Zhang,Jie-mei Tao,Jin-yng Lin,Mei-qiu Wei,Xiao-min Liu,Dan Ke,Shao-xian Hu,Cong Ye,Shu-ling Han,Xiu-yan Yang,Hao Li,Ci-bo Huang,Ming Gao,Pei Lai,Xing-fu Li,Li-jun Song,Rong Mu,Zhan-guo Li
DOI: https://doi.org/10.3969/j.issn.1671-167x.2012.02.005
2012-01-01
Abstract:OBJECTIVE:To investigate the current status of tumor necrosis factor (TNF) inhibitors application in rheumatoid arthritis (RA) patients in China and to analyze the related factors.METHODS:A retrospective survey was conducted in 21 hospitals from different parts of China. The patients with RA were randomly enrolled. Data of their social backgrounds, clinical conditions, usage and adverse effects of TNF inhibitors were collected. The costs of TNF inhibitors and the indirect costs of the disease were calculated. A multivariate Logistic regression analysis was performed to analyze the factors related to TNF inhibitors application.RESULTS:In the study, 1 095 RA patients from July 2009 to November 2010 were enrolled, of whom 112 had received TNF inhibitors, representing 10.2% of the total patients. The patients who received etanercept and infliximab were 7.4% (86/1 095) of the patients and 2.4% (26/1 095), respectively. There were 0.5% of the patients (5/1 095) who had received both of the TNF inhibitors. The patients who had accepted etanercept and treatment duration for less than 3 months and 3-6 months accounted for 38.5% and 25.0% respectively, while those treated with Infliximab were 38.1%. Their health assessment questionnaire (HAQ) scores were 1.1, 0.5 and 0.1, corresponding to treatment duration of infliximab for less than 3, 3-6 and 6-9 months and those were 1.3, 1.0, 0.3 corresponding to treatment duration of etanercept, respectively. Infliximab costs were RMB 24 525.0, 69 300.0 and 96 800.0 Yuan and etanercept costs were RMB 7 394.8, 9 158.6, 54 910.9 Yuan, respectively. Indirect costs for RA patients who accepted infliximab for less than 3, 3-6 and 6-9 months were RMB 365.6, 0 and 158.9 Yuan and those who accepted etanercept were RMB 2 158.4, 288.5 and 180.1 Yuan, respectively. Allergy and infection were the main side-effects of etanercept and both happened in 3.5% of all the patients. Liver damage happened in 2.3% of all the patients, while allergy and infection happened in 6.5% of all the patients who accepted infliximab. Logistic regression analysis showed that patients with higher education experience increased the odds of entering the TNF inhibitors group (OR: 1.292, 95%CI: 1.132-1.473, P=0.000).CONCLUSION:About one-tenth of RA patients in China have accepted TNF inhibitors. Higher education experience is the key factor for using TNF inhibitors.